Transrectal ultrasound-guided (TRUS) biopsy is the gold standard for evaluating suspected prostate malignancies. However, about 20% of the cancer cases are missed by TRUS (c) mainly due to missed tumors in the peri-urethral and the anterior area of the prostate. Transurethral sampling may enable sampling from these hard-to-reach areas, estimated at 15-20% of prostate biopsies (c).
Currently there is no minimally invasive access to the deep, lateral and anterior core fields of the prostate.
(c) Norberg M. et al, Urology 1997; 50:562